- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Natco Pharma transfers Lenalidomide ANDA to Arrow International
Hyderabad: Natco Pharma Limited has recently announced that the company has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, l0mg, l5mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties. Arrow International...
Hyderabad: Natco Pharma Limited has recently announced that the company has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, l0mg, l5mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.
This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.
Arrow International Limited (an affiliate of Teva Pharmaceutical Industries Ltd) is the marketing partner of NATCO for this product in the US market.
The ANDA was approved by U.S. Food and Drug Administration (USFDA) in May 2021 with final approval in the 5mg, l0mg, l5mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.
Read also: Natco Pharma marketing partner gets USFDA nod for Carfilzomib Vials ANDA
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751